YS Biopharma Co., Ltd. (YS)

YS Biopharma Co. Balance Sheet

Financials in millions CNY. Fiscal year is April - March.

Year	2022	2021	2020
Cash & Equivalents	370.37	271.07	390.46
Cash & Cash Equivalents	370.37	271.07	390.46
Cash Growth	36.63%	-30.58%	-
Receivables	463.05	308.56	256.05
Inventory	185.38	166.51	81.44
Other Current Assets	17.18	18.64	5.26
Total Current Assets	1,036	764.76	733.2
Property, Plant & Equipment	582.89	565	253.45
Goodwill and Intangibles	78.06	80.72	83.78
Other Long-Term Assets	22.83	31.27	96.74
Total Long-Term Assets	683.78	676.99	433.97
Total Assets	1,720	1,442	1,167
Accounts Payable	80.44	30.81	16.38
Deferred Revenue	25.9	32.35	33.01
Current Debt	198.49	116.06	3.79
Other Current Liabilities	353.93	296.7	291.87
Total Current Liabilities	658.76	475.91	345.04
Long-Term Debt	300.14	264.53	14.65
Other Long-Term Liabilities	32.4	30.05	30.88
Total Long-Term Liabilities	332.54	294.59	45.54
Total Liabilities	991.3	770.5	390.58
Total Debt	498.63	380.59	18.44
Debt Growth	31.02%	1963.98%	-
Retained Earnings	-1,874.04	-1,590.57	-1,353.9
Comprehensive Income	-54.41	83.09	44.22
Shareholders' Equity	728.45	-698.97	-508.86
Net Cash / Debt	-128.26	-109.52	372.02
Net Cash Per Share	-1.38	-1.77	6.02
Working Capital	377.22	288.85	388.16
Book Value Per Share	7.83	-11.30	-8.23

Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).